onclive.com is built with Sanity, hosted on AWS behind Cloudflare. It measures traffic with Google Analytics and Google Tag Manager. It sends email through Attentive and Amazon SES.
| Technology | Version | First seen |
|---|---|---|
| CMS & Site Builders1 | ||
| – | 10 Nov 2026 | |
| JavaScript Frameworks & Libraries2 | ||
| – | 10 Nov 2026 | |
| Frontend Build Tools & CSS4 | ||
| 3.32.2 | 10 Nov 2026 | |
| CDN & Hosting3 | ||
| – | 10 Nov 2026 | |
| Analytics & Tag Management4 | ||
| – | 10 Nov 2026 | |
| Advertising & Affiliate Tracking7 | ||
| – | 10 Nov 2026 | |
| Email Marketing & Lead Capture2 | ||
| – | 10 Nov 2026 | |
| Transactional Email2 | ||
| – | 10 Nov 2026 | |
| A/B Testing, Personalization & Feature Flags1 | ||
| – | 10 Nov 2026 | |
| Consent Management & Privacy1 | ||
| – | 10 Nov 2026 | |
| Fonts & Icon Fonts1 | ||
| – | 10 Nov 2026 | |
| Security, WAF & Bot Protection1 | ||
| – | 10 Nov 2026 | |
Registration from the registry's RDAP record, the certificate the site serves, and its rank in public traffic lists.
The crew hasn’t read this site’s colors yet. We read a palette when we capture a site’s screenshot, busiest sites first. Meanwhile, browse palettes from other sites.
Counted from every stack change we've recorded: of the sites we watched running one of this site's tools, how many went on to add another. A pattern across sites, not a forecast for this one.
From what the site says about itself, and account IDs it shares with other sites.
us-smtp-inbound-1.mimecast.comus-smtp-inbound-2.mimecast.comkiki.ns.cloudflare.compete.ns.cloudflare.comfacebook-domain-verification=3sc793d06xovum6gxpp0nuskqt2hpfbox-domain-verification=08f2782044aaa41f0562136c626c81f8c3aa38e9604f223712e1c6ac04bc97e9v=spf1 include:us._netblocks.mimecast.com ip4:97.65.79.93 ip4:64.132.221.30 ~alladobe-idp-site-verification=0363298ae51d1cc777f0d75c3ec91e5c51fc83f203125e52f8ae7fdd1fef686aknowbe4-site-verification=1fc3701aa0d3b200af3e4de0c45aa24fgoogle-site-verification=8xy7ZkTfs47149MjNv0xzVpVc1J1M3eEYJNdieOwBvk0ed1fe018aa82d07994ff04a51860b63MS=ms69104256v=DMARC1; p=quarantine; rua=mailto:email_deployment@mjhlifesciences.com; ruf=mailto:email_deployment@mjhlifesciences.com; fo=1; pct=100;User-agent: * Disallow: /search Disallow: /preview/ Disallow: /*[*]*$ Sitemap: https://www.onclive.com/sitemap.xml Sitemap: https://www.onclive.com/sitemap-news.xml
# OncLive > OncLive - Healthcare Publication - Base URL: https://www.onclive.com - Generated: 2026-11-10T00:12:04.621Z - Content updates: multiple times daily ## Content Access for AI Agents This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML. **Supported content types:** - `text/markdown` — Clean Markdown with YAML frontmatter - `text/plain` — Plain text (same as Markdown) - `text/html` — Default HTML response **Example request:** ``` curl -H "Accept: text/markdown" https://www.onclive.com/view/article-slug ``` **YAML frontmatter schema** (returned with every Markdown response): | Field | Type | Description | |-------|------|-------------| | `title` | string | Article headline | | `description` | string | Summary/excerpt (max 300 chars) | | `url` | string | Canonical article URL | | `canonical_url` | string | Canonical URL if different from `url` | | `published` | ISO 8601 | Original publication date | | `modified` | ISO 8601 | Last modification date | | `authors` | string[] | Author display names | | `content_type` | string | Content category (e.g., "News", "Clinical") | | `categories` | string[] | Taxonomy categories | | `tags` | string[] | SEO tags | | `image` | string | Featured image URL | | `publisher` | string | Publication/site name | **Discovery headers** (included on all responses): - `Link: <https://www.onclive.com/llms.txt>; rel="llms"` — RFC 8288 link to this file - `X-Llms-Txt: https://www.onclive.com/llms.txt` — Explicit discovery header ## Usage Policy - Robots policy: [https://www.onclive.com/robots.txt](https://www.onclive.com/robots.txt) - Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329) - Rate guidance: prefer RSS and sitemap feeds over crawling individual pages - Attribution: All content © MJH Life Sciences. Include source URLs when citing. ## Content Categories - [Blood Club](https://www.onclive.com/blood-club) - [Breaking News](https://www.onclive.com/breaking-news) - [COVID-19](https://www.onclive.com/covid-19) - [Clinical](https://www.onclive.com/clinical) - [Clinical Trials in Focus](https://www.onclive.com//clinical-trials-in-focus) - [Conference](https://www.onclive.com/conference) - [Emerging Biomarker](https://www.onclive.com/emerging-biomarker) - [Events](https://www.onclive.com/events) - [Exhibitor](https://www.onclive.com/exhibitor) - [Immunotherapy in GU Cancers](https://www.onclive.com/immunotherapy-in-gu-cancers) - [Immunotherapy in Lung Cancer](https://www.onclive.com/immunotherapy-in-lung-cancer) - [Immunotherapy in Melanoma](https://www.onclive.com/immunotherapy-in-melanoma) - [Insights](https://www.onclive.com/insights) - [Insights Video Series](https://www.onclive.com/insights-video-series) - [Leukemia Experts Reflect on Defining Moments, Career Experiences, and Gender Bias as Women in the Field](https://www.onclive.com/leukemia-experts-reflect-on-defining-moments-career-experiences-and-gender-bias-as-women-in-the-field) - [Medical Content](https://www.onclive.com/medical-content) - [NO ADS](https://www.onclive.com/noads) - [National Fellows Forum](https://www.onclive.com/national-fellows-forum) - [News](https://www.onclive.com/news) - [Onc App Featured Content](https://www.onclive.com/app-featured-content) - [OncClub](https://www.onclive.com/oncclub) - [OncLive News Network®](https://www.onclive.com/news-network) - [OncLive Peer Exchange® ](https://www.onclive.com/peer-exchange) - [OncLive TV](https://www.onclive.com/onclive-tv) - [Oncology Nursing News](https://www.onclive.com/nurses) - [Podcasts](https://www.onclive.com/podcasts) - [Publications](https://www.onclive.com/publications) - [Rapid Readouts](https://www.onclive.com/rapid-readouts) - [Scientific Interchange & Workshop](https://www.onclive.com/scientific-interchange-and-workshop) - [Special Reports in Personalized Cancer Care](https://www.onclive.com/personalized-medicine) - [Sponsored](https://www.onclive.com/sponsored) - [The Talk](https://www.onclive.com/the-talk) - [Thoracic Night Live](https://www.onclive.com/thoracic-night-live) - [Video Series](https://www.onclive.com/video-series) - [Webinars](https://www.onclive.com/webinars) ## Featured Content - [Dr Backes on BEHOLD-1 Data With Mocertatug Rezetecan in Platinum-Resistant Ovarian Cancer](https://www.onclive.com/view/dr-backes-on-behold-1-data-with-mocertatug-rezetecan-in-platinum-resistant-ovarian-cancer): Floor Backes, MD, discusses BEHOLD-1 data for the B7-H4–directed ADC mocertatug rezetecan in platinum-resistant ovarian cancer. - [Dr Patel on How Zidesamtinib Data From ARROS-1 Compare With Taletrectinib Data From TRUST-I/TRUST-II in ROS1-Positive NSCLC ](https://www.onclive.com/view/dr-patel-on-how-zidesamtinib-data-from-arros-1-compare-with-taletrectinib-data-from-trust-i-trust-ii-in-ros1-positive-nsclc): Shiven B. Patel, MD, MBA, FACP, discusses how zidesamtinib compares with taletrectinib in ROS1-positive non–small cell lung cancer. - [Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple Myeloma](https://www.onclive.com/view/melflufen-gains-eu-expansion-in-third-line-lenalidomide-refractory-multiple-myeloma): The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy. - [Nogapendekin Alfa Inbakicept Plus BCG Meets Primary End Point in BCG-Naive NMIBC](https://www.onclive.com/view/nogapendekin-alfa-inbakicept-plus-bcg-meets-primary-end-point-in-bcg-naive-nmibc): Anktiva plus BCG improved efficacy vs BCG alone in cohort A of QUILT-2.005 in BCG-naive NMIBC. - [Gedatolisib sNDA Accepted by FDA for PIK3CA-Mutated, HR+, HER2– Advanced Breast Cancer](https://www.onclive.com/view/gedatolisib-snda-accepted-by-fda-for-pik3ca-mutated-hr-her2-advanced-breast-cancer): The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. - [FDA Flashback: Hematologic Cancer Decisions and News From October 2026](https://www.onclive.com/view/fda-flashback-hematologic-cancer-decisions-and-news-from-october-2026): Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL. - [City of Hope Researchers Harness the Microbiome to Prevent Deadly Bloodstream Infections](https://www.onclive.com/view/city-of-hope-researchers-harness-the-microbiome-to-prevent-deadly-bloodstream-infections): SER-155 showed early promise in reducing bloodstream infections in patients undergoing donor stem cell transplants for blood cancers. - [Dr Negrao on Olomorasib Plus Chemoimmunotherapy in KRAS G12C–Mutant NSCLC](https://www.onclive.com/view/dr-negrao-on-olomorasib-plus-chemoimmunotherapy-in-kras-g12c-mutant-nsclc): Marcelo V. Negrao, MD, discusses updated efficacy and safety data for first-line olomorasib plus chemoimmunotherapy in KRAS G12C–mutant NSCLC. - [Breast Cancer’s Fastest-Moving Questions: Which Expert Recommendations Have Held Up?](https://www.onclive.com/view/breast-cancer-s-fastest-moving-questions-which-expert-recommendations-have-held-up-): Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026. - [BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R Myeloma](https://www.onclive.com/view/bcma-directed-bispecifics-and-adcs-broaden-treatment-sequencing-options-in-r-r-myeloma): During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced. ## Feeds and Indexes - [RSS Feed](https://www.onclive.com/rss.xml): Latest articles in XML syndication format - [Sitemap](https://www.onclive.com/sitemap.xml): Complete URL index for all published pages - [News Sitemap](https://www.onclive.com/sitemap-news.xml): Recent articles optimized for news indexing - [Authors Directory](https://www.onclive.com/authors): Browse all contributors and their published work
google.com, pub-7203212329370932, DIRECT, f08c47fec0942fa0
| – |
| 10 Nov 2026 |
| – |
| 10 Nov 2026 |
| – | 10 Nov 2026 |
| – | 10 Nov 2026 |
| – |
| 10 Nov 2026 |
| – | 10 Nov 2026 |
| – |
| 10 Nov 2026 |
| – | 10 Nov 2026 |
| – | 10 Nov 2026 |
| – |
| 10 Nov 2026 |
| – | 10 Nov 2026 |
| – | 10 Nov 2026 |
| – | 10 Nov 2026 |
| – | 10 Nov 2026 |
| – | 10 Nov 2026 |
| – |
| 10 Nov 2026 |
| – |
| 10 Nov 2026 |